<p>Cogent Biosciences, Inc.（纳斯达克代码：COGT - 免费报告）- Wedbush 的分析师在 8 月 5 日星期二向投资者发布的报告中下调了对 Cogent Biosciences 2025 财年的每股收益预期。Wedbush 分析师 D. Nierengarten 现在预计该科技公司将发布每股收益（$2.21），低于之前的预期（$1.49）。Wedbush 目前对该股票的评级为 “中性”，目标价为 10.00 美元。市场普遍预计 Cogent Biosciences 当前全年的每股收益为（$2.42）。</p>
<p>其他几家券商最近也发布了关于 COGT 的报告。HC Wainwright 将 Cogent Biosciences 的目标价从 22.00 美元下调至 21.00 美元，并在周三的报告中对该公司给予 “买入” 评级。Needham &amp; Company LLC 在 6 月 17 日星期二的研究报告中重申了对 Cogent Biosciences 的 “持有” 评级。Jefferies Financial Group 在 7 月 7 日星期一的报告中将 Cogent Biosciences 的目标价从 23.00 美元上调至 28.00 美元，并给予该股票 “买入” 评级。Guggenheim 在 7 月 8 日星期二的报告中重申了 “买入” 评级，并将 Cogent Biosciences 的目标价设定为 17.00 美元。最后，花旗集团在 7 月 18 日星期五的报告中将 Cogent Biosciences 的目标价从 15.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。三位研究分析师对该股票给予了持有评级，七位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，Cogent Biosciences 目前的共识评级为 “适度买入”，平均目标价为 18.70 美元。</p>
<p>获取 <strong>Cogent Biosciences</strong> 的提醒：</p>
<p><strong>查看我们对 Cogent Biosciences 的最新股票分析</strong></p>
<h2>Cogent Biosciences 股票上涨 1.6%</h2>
<p>COGT 股票在周五上涨 0.18 美元，达到 11.04 美元。该公司的交易量为 87,926 股，而其平均交易量为 2,009,252 股。该公司的 50 日移动平均线为 9.13 美元，200 日移动平均线为 7.35 美元。Cogent Biosciences 的年低为 3.72 美元，年高为 12.97 美元。该股票的市值为 12.6 亿美元，市盈率为-6.21，贝塔值为 0.36。</p>
<p>Cogent Biosciences（纳斯达克代码：COGT - 获取免费报告）最近在 8 月 5 日星期二发布了季度收益数据。该科技公司报告的季度每股收益为（$0.53），超出市场普遍预期的（$0.55）0.02 美元。</p>
<h2>机构投资者对 Cogent Biosciences 的看法</h2>
<p>机构投资者和对冲基金最近买卖了该股票的股份。ProShare Advisors LLC 在第二季度将其在 Cogent Biosciences 的股份增加了 4.1%。ProShare Advisors LLC 现在拥有 26,021 股该科技公司的股票，价值 187,000 美元，此前在此期间购买了 1,020 股。Corton Capital Inc.在第二季度将其在 Cogent Biosciences 的股份增加了 6.4%。Corton Capital Inc.现在拥有 17,438 股该科技公司的股票，价值 125,000 美元，此前在此期间购买了 1,046 股。Balyasny Asset Management L.P.在第四季度将其在 Cogent Biosciences 的股份增加了 8.8%。Balyasny Asset Management L.P.现在拥有 20,805 股该科技公司的股票，价值 162,000 美元，此前在此期间购买了 1,687 股。49 Wealth Management LLC 在第二季度将其在 Cogent Biosciences 的股份增加了 19.0%。49 Wealth Management LLC 现在拥有 15,508 股该科技公司的股票，价值 111,000 美元，此前在上个季度购买了 2,476 股。最后，亚利桑那州退休系统在第一季度将其在 Cogent Biosciences 的股份增加了 18.0%。亚利桑那州退休系统现在拥有 20,567 股该科技公司的股票，价值 123,000 美元，此前在上个季度购买了 3,142 股。</p>
<h2>内部买卖</h2>
<p>在相关消息中，董事 Fairmount Funds Management Llc 在 7 月 10 日星期四的交易中购买了 2,777,777 股该公司的股票。这些股票的平均购买价格为每股 9.00 美元，总交易额为 24,999,993.00 美元。收购完成后，该董事直接持有该公司 9,003,418 股股票，价值 81,030,762 美元。这笔交易代表了他们持股比例的 44.62% 的增加。该收购在向 SEC 的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司 7.29% 的股份。</p>
<h2>Cogent Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cogent Biosciences, Inc.是一家生物技术公司，专注于开发针对基因定义疾病的精准疗法。其主要产品候选包括 bezuclastinib（CGT9486），这是一种选择性酪氨酸激酶抑制剂，旨在针对 KIT 受体酪氨酸激酶中的突变，包括驱动系统性肥大细胞增生的 KIT D816V 突变，以及在晚期胃肠道间质瘤患者中发现的 KIT 外显子 17 中的其他突变。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Cogent Biosciences 更好</li>
<li>三只可以升级您投资组合的家居改善股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>什么是日经 225 指数？</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
<li>什么是国债？</li>
<li>亚马逊在 IonQ 中获得股权投资——有什么潜在收益？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Cogent Biosciences 吗？</h2>
<p>在你考虑 Cogent Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Cogent Biosciences 并不在名单上。</p>
<p>虽然 Cogent Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COGT

<p>Wedbush 分析师将 Cogent Biosciences (NASDAQ:COGT) 的 2025 财年每股收益预期从 ($1.49) 下调至 ($2.21)。当前的市场共识预期为每股 ($2.42)。Wedbush 维持 “中性” 评级，目标价为 $10.00。其他券商的评级各不相同，目标价范围在 $17.00 到 $28.00 之间。COGT 股票最近交易价格为 $11.04，上涨 1.6%。该公司在上个季度报告的每股收益为 ($0.53)，超出预期。内部人士的买入使持股比例增加了 44.62%</p>

<p>Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Wedbush cut their FY2025 earnings per share estimates for Cogent Biosciences in a note issued to investors on Tuesday, August 5th. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings of ($2.21) per share for the year, down from their previous estimate of ($1.49). Wedbush currently has a &#34;Neutral&#34; rating and a $10.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share.</p>
<div class="lb-trans"><p>Cogent Biosciences, Inc.（纳斯达克代码：COGT - 免费报告）- Wedbush 的分析师在 8 月 5 日星期二向投资者发布的报告中下调了对 Cogent Biosciences 2025 财年的每股收益预期。Wedbush 分析师 D. Nierengarten 现在预计该科技公司将发布每股收益（$2.21），低于之前的预期（$1.49）。Wedbush 目前对该股票的评级为 “中性”，目标价为 10.00 美元。市场普遍预计 Cogent Biosciences 当前全年的每股收益为（$2.42）。</p>
</div><p>Several other brokerages also recently issued reports on COGT. HC Wainwright lowered their price target on shares of Cogent Biosciences from $22.00 to $21.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday. Needham &amp; Company LLC reiterated a &#34;hold&#34; rating on shares of Cogent Biosciences in a research report on Tuesday, June 17th. Jefferies Financial Group lifted their target price on Cogent Biosciences from $23.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, July 7th. Guggenheim restated a &#34;buy&#34; rating and set a $17.00 price target on shares of Cogent Biosciences in a report on Tuesday, July 8th. Finally, Citigroup raised their price target on shares of Cogent Biosciences from $15.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Cogent Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $18.70.</p>
<div class="lb-trans"><p>其他几家券商最近也发布了关于 COGT 的报告。HC Wainwright 将 Cogent Biosciences 的目标价从 22.00 美元下调至 21.00 美元，并在周三的报告中对该公司给予 “买入” 评级。Needham &amp; Company LLC 在 6 月 17 日星期二的研究报告中重申了对 Cogent Biosciences 的 “持有” 评级。Jefferies Financial Group 在 7 月 7 日星期一的报告中将 Cogent Biosciences 的目标价从 23.00 美元上调至 28.00 美元，并给予该股票 “买入” 评级。Guggenheim 在 7 月 8 日星期二的报告中重申了 “买入” 评级，并将 Cogent Biosciences 的目标价设定为 17.00 美元。最后，花旗集团在 7 月 18 日星期五的报告中将 Cogent Biosciences 的目标价从 15.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。三位研究分析师对该股票给予了持有评级，七位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，Cogent Biosciences 目前的共识评级为 “适度买入”，平均目标价为 18.70 美元。</p>
</div><p>Get <strong>Cogent Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cogent Biosciences</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cogent Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Cogent Biosciences 的最新股票分析</strong></p>
</div><h2>Cogent Biosciences Stock Up 1.6%</h2>
<div class="lb-trans"><h2>Cogent Biosciences 股票上涨 1.6%</h2>
</div><p>Shares of COGT stock traded up $0.18 on Friday, reaching $11.04. The company had a trading volume of 87,926 shares, compared to its average volume of 2,009,252. The business's 50-day moving average is $9.13 and its 200 day moving average is $7.35. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.97. The stock has a market capitalization of $1.26 billion, a PE ratio of -6.21 and a beta of 0.36.</p>
<div class="lb-trans"><p>COGT 股票在周五上涨 0.18 美元，达到 11.04 美元。该公司的交易量为 87,926 股，而其平均交易量为 2,009,252 股。该公司的 50 日移动平均线为 9.13 美元，200 日移动平均线为 7.35 美元。Cogent Biosciences 的年低为 3.72 美元，年高为 12.97 美元。该股票的市值为 12.6 亿美元，市盈率为-6.21，贝塔值为 0.36。</p>
</div><p>Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The technology company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02.</p>
<div class="lb-trans"><p>Cogent Biosciences（纳斯达克代码：COGT - 获取免费报告）最近在 8 月 5 日星期二发布了季度收益数据。该科技公司报告的季度每股收益为（$0.53），超出市场普遍预期的（$0.55）0.02 美元。</p>
</div><h2>Institutional Investors Weigh In On Cogent Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 Cogent Biosciences 的看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC grew its stake in Cogent Biosciences by 4.1% in the 2nd quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company's stock valued at $187,000 after purchasing an additional 1,020 shares during the period. Corton Capital Inc. raised its stake in shares of Cogent Biosciences by 6.4% during the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company's stock valued at $125,000 after purchasing an additional 1,046 shares during the period. Balyasny Asset Management L.P. increased its position in shares of Cogent Biosciences by 8.8% during the fourth quarter. Balyasny Asset Management L.P. now owns 20,805 shares of the technology company's stock valued at $162,000 after buying an additional 1,687 shares during the period. 49 Wealth Management LLC lifted its stake in Cogent Biosciences by 19.0% in the 2nd quarter. 49 Wealth Management LLC now owns 15,508 shares of the technology company's stock worth $111,000 after purchasing an additional 2,476 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of Cogent Biosciences by 18.0% in the first quarter. Arizona State Retirement System now owns 20,567 shares of the technology company's stock worth $123,000 after buying an additional 3,142 shares in the last quarter.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该股票的股份。ProShare Advisors LLC 在第二季度将其在 Cogent Biosciences 的股份增加了 4.1%。ProShare Advisors LLC 现在拥有 26,021 股该科技公司的股票，价值 187,000 美元，此前在此期间购买了 1,020 股。Corton Capital Inc.在第二季度将其在 Cogent Biosciences 的股份增加了 6.4%。Corton Capital Inc.现在拥有 17,438 股该科技公司的股票，价值 125,000 美元，此前在此期间购买了 1,046 股。Balyasny Asset Management L.P.在第四季度将其在 Cogent Biosciences 的股份增加了 8.8%。Balyasny Asset Management L.P.现在拥有 20,805 股该科技公司的股票，价值 162,000 美元，此前在此期间购买了 1,687 股。49 Wealth Management LLC 在第二季度将其在 Cogent Biosciences 的股份增加了 19.0%。49 Wealth Management LLC 现在拥有 15,508 股该科技公司的股票，价值 111,000 美元，此前在上个季度购买了 2,476 股。最后，亚利桑那州退休系统在第一季度将其在 Cogent Biosciences 的股份增加了 18.0%。亚利桑那州退休系统现在拥有 20,567 股该科技公司的股票，价值 123,000 美元，此前在上个季度购买了 3,142 股。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, Director Fairmount Funds Management Llc bought 2,777,777 shares of the company's stock in a transaction dated Thursday, July 10th. The shares were bought at an average price of $9.00 per share, for a total transaction of $24,999,993.00. Following the completion of the acquisition, the director directly owned 9,003,418 shares of the company's stock, valued at $81,030,762. This trade represents a 44.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.29% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Fairmount Funds Management Llc 在 7 月 10 日星期四的交易中购买了 2,777,777 股该公司的股票。这些股票的平均购买价格为每股 9.00 美元，总交易额为 24,999,993.00 美元。收购完成后，该董事直接持有该公司 9,003,418 股股票，价值 81,030,762 美元。这笔交易代表了他们持股比例的 44.62% 的增加。该收购在向 SEC 的法律文件中披露，可以通过此链接访问。公司内部人士持有该公司 7.29% 的股份。</p>
</div><h2>Cogent Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Cogent Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.</p>
<div class="lb-trans"><p>Cogent Biosciences, Inc.是一家生物技术公司，专注于开发针对基因定义疾病的精准疗法。其主要产品候选包括 bezuclastinib（CGT9486），这是一种选择性酪氨酸激酶抑制剂，旨在针对 KIT 受体酪氨酸激酶中的突变，包括驱动系统性肥大细胞增生的 KIT D816V 突变，以及在晚期胃肠道间质瘤患者中发现的 KIT 外显子 17 中的其他突变。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cogent Biosciences</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>What is the Nikkei 225 index?</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>What Are Treasury Bonds?</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Cogent Biosciences 更好</li>
<li>三只可以升级您投资组合的家居改善股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>什么是日经 225 指数？</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
<li>什么是国债？</li>
<li>亚马逊在 IonQ 中获得股权投资——有什么潜在收益？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=COGT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cogent Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Cogent Biosciences 吗？</h2>
</div><p>Before you consider Cogent Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cogent Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Cogent Biosciences 并不在名单上。</p>
</div><p>While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cogent Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Wedbush 对 Cogent Biosciences 2025 财年收益的展望持悲观态度